ELI LILLY AND COMPANY
Ownership & governance
Executives 5Directors 10Avg age 58Avg tenure 9.3y
DR
David Ricks
Chief Executive Officer
Age 58Since 2016-12-31Profile →
+14
Executives5
Board of directors10
JF
Jon Fyrwald→
Director/Board Member
Age 66Since 2004-12-31
RA
Ralph Alvarez→
Director/Board Member
Age 70Since 2009-03-31
KB
Katherine Baicker→
Director/Board Member
Age 54Since 2011-12-11
DR
David Ricks→
Chairman
Age 58Since 2017-05-31
WK
William Kaelin→
Director/Board Member
Age 68Since 2012-06-03
JL
Juan Luciano→
Director/Board Member
Age 64Since 2016-01-31
JJ
Jamere Jackson→
Director/Board Member
Age 56Since 2016-09-30
GG
Gabrielle Greene-Sulzberger→
Director/Board Member
Age 65Since 2021-01-24
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| Lilly Endowment, Inc. | 9.758 % | 91,896,978 |
| Lilly Endowment, Inc. | 9.757 % | 91,881,150 |
| Vanguard Capital Management LLC | 5.666 % | 53,361,774 |
| PNC Wealth Management LLC | 5.429 % | 51,125,662 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Daniel Skovronsky | Chief Tech/Sci/R&D Officer | — | - |
| David Ricks | Chairman | 2017-05-31 | - |
| David Ricks | Chief Executive Officer | 2016-12-31 | - |
| Diogo Rau | Chief Tech/Sci/R&D Officer | 2021-05-16 | - |
| Lucas Montarce | Director of Finance/CFO | 2024-09-08 | - |
| Thomas Fuchs | Chief Tech/Sci/R&D Officer | 2024-10-20 | - |
| Gabrielle Greene-Sulzberger | Director/Board Member | 2021-01-24 | - |
| Jamere Jackson | Director/Board Member | 2016-09-30 | - |
Registry · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| Lilly Asia Ventures Fund II LP | Investment Managers |
| ELI Lilly & Company (India) Pvt Ltd. | Pharmaceuticals: Major |
| ELI Lilly & Company (India) Pvt Ltd. | Pharmaceuticals: Major |
| Eli Lilly Services India Pvt Ltd. | Pharmaceuticals: Major |
| Eli Lilly Services India Pvt Ltd. | Pharmaceuticals: Major |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 1,328.05Range 930–1,600Analysts 30
930Mean 1,328.051,600
- Strong buy 6
- Buy 20
- Hold 3
- Sell 1
- Strong sell 1
Broker actions40 of 458
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Reiterated | Outperform | 1,500 | 2026-10-12 |
| Cantor Fitzgerald | Maintained | Overweight | 1,440 | 2026-10-08 |
| Morgan Stanley | Maintained | Overweight | 1,430 | 2026-10-07 |
| JP Morgan | Maintained | Overweight | 1,500 | 2026-09-28 |
| TD Cowen | Reiterated | Buy | 1,250 | 2026-09-22 |
| Guggenheim | Maintained | Buy | 1,284 | 2026-09-18 |
| HSBC | Maintained | Reduce | 940 | 2026-09-10 |
| Truist Securities | Maintained | Buy | 1,376 | 2026-08-07 |
| Wells Fargo | Maintained | Overweight | 1,330 | 2026-08-06 |
| Cantor Fitzgerald | Maintained | Overweight | 1,410 | 2026-08-06 |
| Citigroup | Maintained | Buy | 1,600 | 2026-07-15 |
| Bernstein | Maintained | Outperform | 1,385 | 2026-07-14 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.